Skip to main content

Table 1 Psoriasin expression and clinical/pathological characteristics of lung cancer

From: The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions

Clinical/pathological features Sample no. Median (Copy no.) IQR P-value
Tumour tissue 83 0.17 0-27.5  
Background tissue 69 0.01 0-1 0.0195
Paired tumour tissue 61 0.17 0-24.1  
Paired background tissue 61 0.01 0-1 0.0251
Gender     
Male 47    
Female 25    
Histology     
Squamous carcinoma 30 0.4 0-45  
Adenocarcinoma 37 0.1 0-4.1 0.035
Others 6 N/A N/A  
TNM staging     
I 22 0 0-15.3  
II 16 0.1 0-110.8 0.22
III 34 1 0-43 0.085
Tumour differentiation     
High 5 0.1 0-27.2  
Med 33 1 0-42 0.17
Low 11 0.01 0-1.15 0.51
Tumour status     
T1 8 3.99 0-13.87  
T2 41 0 0-22.2 0.989
T3 23 25.6 0-225.6 0.081
Lymph node status     
N0 24 0 0-18  
N1 13 0.1 0-77.6 0.93
N2 25 1 0-42 0.51
Smoking status     
Former or current smoker 49 0.2 0-43  
Non smoker 23 0 0-12 0.0372